PLA2G7 and atherosclerosis: Although darapladib, the most advanced Lp-PLA2 inhibitor, failed to meet the primary endpoint in extensive phase III trials involving patients with atherosclerosis and stable coronary heart disease receiving standard medical treatment [44, 45], the study of Lp-PLA2 remains ongoing [27].